Markets · 1 sources covering this

RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year

Revolution Medicines won US approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday. It’s one of the first medicines to broadly target RAS, a protein tied to tumor growth that’s…

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·1h ago
RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year
Revolution Medicines won US approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expensive cancer treatments in history. The company branded it Rasonque and made it available starting Wednesday. It’s one of the first medicines to broadly target RAS, a protein tied to tumor growth that’s…
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/97dddbe32c420a2951f6497769726b2ac653f6f8"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year"></iframe>

RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year

How 1 sources are covering this